ATI RN
ATI Pharmacology Proctored Exam Questions
Question 1 of 5
A healthcare provider is preparing to administer Belimumab to a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare provider plan to take?
Correct Answer: D
Rationale: Correct Answer: Monitoring the client for hypersensitivity reactions is crucial when administering Belimumab due to its known potential for severe infusion reactions and anaphylaxis. The healthcare provider should closely observe the client during the administration to promptly identify and manage any hypersensitivity reactions that may occur. Choice A is incorrect because warming Belimumab is not necessary before administration. Choice B is incorrect as Belimumab should not be administered as an IV bolus over 5 minutes; it should be given as an IV infusion over a longer duration. Choice C is incorrect as Belimumab should not be diluted in a 5% dextrose and water solution.
Question 2 of 5
A healthcare provider is preparing to administer an Opioid agonist to a client who has acute pain. Which of the following complications should the provider monitor?
Correct Answer: A
Rationale: The correct answer is urinary retention. Opioid agonists like morphine can suppress the awareness of bladder fullness, leading to urinary retention. This complication can result in significant discomfort and potential urinary tract issues if not promptly addressed. Tachypnea (increased respiratory rate) is a common side effect of opioids but is not a specific complication related to urinary retention. Hypertension is not typically associated with opioid agonists and is more commonly seen with opioid antagonists. An irritating cough is not a known complication of opioid agonists and is not directly related to the effect opioids have on the urinary system.
Question 3 of 5
A healthcare provider is planning care for a client with brain cancer experiencing headaches. Which of the following adjuvant medications is indicated for this client?
Correct Answer: A
Rationale: Dexamethasone, a glucocorticoid, is indicated for clients with brain cancer experiencing headaches as it decreases inflammation and swelling. It is commonly used to reduce cerebral edema and relieve pressure caused by the tumor. Methylphenidate (Choice B) is a central nervous system stimulant used in conditions like ADHD and narcolepsy, not for brain cancer headaches. Hydroxyzine (Choice C) is an antihistamine used for anxiety and allergic conditions, not indicated for brain cancer headaches. Amitriptyline (Choice D) is a tricyclic antidepressant used for depression, neuropathic pain, and migraine prophylaxis, but not typically indicated for brain cancer headaches.
Question 4 of 5
A client with migraine headaches is starting prophylaxis therapy with Propranolol. Which finding in the client's history should the nurse report to the provider?
Correct Answer: D
Rationale: Propranolol is contraindicated in clients with first-degree heart block due to its negative inotropic and chronotropic effects. The nurse should report this finding to the provider to consider an alternative therapy to prevent potential worsening of cardiac conduction abnormalities. Choices A, B, and C are not directly contraindications to Propranolol therapy for migraine headaches and do not pose immediate risks that would require reporting to the provider.
Question 5 of 5
While caring for a client taking Propylthiouracil, for which of the following adverse effects should the nurse monitor?
Correct Answer: A
Rationale: When a client is taking Propylthiouracil, the nurse should monitor for bradycardia as it is an adverse effect of this medication. Propylthiouracil can lead to a decrease in heart rate, which is known as bradycardia. Monitoring for this adverse effect is crucial to ensure the client's safety and well-being while on this medication. The other options, such as insomnia, heat intolerance, and weight loss, are not commonly associated adverse effects of Propylthiouracil. Therefore, they are incorrect choices for monitoring while the client is on this medication.